CORDIS
EU research results

CORDIS

English EN
GlucoCEST Imaging of Neoplastic Tumours

GlucoCEST Imaging of Neoplastic Tumours

Objective

Cancer is one of the most devastating diseases the world is currently facing, accounting for 7.6 million deaths in 2008 (WHO). Cancer is usually detected through advanced medical imaging. Early detection is very important as it increases the chances of survival and the potential for full recovery. Further, The high level of sophistication in treating cancer has led to a new unsolved problem, the differentiation between treatment effect, regrowth or pseudo-progression of the tumour. Here, we aim to develop and bring to the clinic a potentially disruptive new technology to characterize and image glucose delivery, uptake and metabolism in cancer.
Recently we managed to demonstrate the sensitivity of a technique, named glucose-based Chemical Exchange Saturation Transfer (glucoCEST), to detect native (α-D-glucose) glucose uptake in tumours. In addition, recent developments have shown glucose analogues, such as 3-oxy-methyl-D-glucose (3OMG) can be used as potential non-metabolisable tracers using the same technique.
In this proposal, we aim to bring the combination of native D-glucose and 3-oxy-methyl-D-glucose as a combined examination to the clinic to assess cancer glucose uptake and metabolism, thereby providing a cheap, widely available, more comprehensive, non-invasive alternative to nuclear medicine techniques currently used for cancer assessment within Europe.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY COLLEGE LONDON

Address

Gower Street
Wc1e 6bt London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 687 712

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

TEL AVIV UNIVERSITY

Israel

EU Contribution

€ 848 325

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 739 125

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 746 912

UNIVERSITAT ZURICH

Switzerland

OLEA MEDICAL

France

EU Contribution

€ 731 475

BRACCO IMAGING SPA

Italy

EU Contribution

€ 645 250

EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG

Austria

EU Contribution

€ 399 000

Project information

Grant agreement ID: 667510

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 454 612

  • EU contribution

    € 5 797 799

Coordinated by:

UNIVERSITY COLLEGE LONDON

United Kingdom